AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20840875
Drug: Standard cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cancer treatments (controls)
Trial: 16223206
Drug: rifaximin 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rifaximin 1,200 mg/day
Trial: 16223206
Drug: lactulose 10-20
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: lactulose 10-20 g three times daily
Trial: 10550153
Drug: 13‐cis‐retinoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13‐cis‐retinoic acid (13‐CRA) 30 mg orally daily for 6 months
Trial: 7495926
Drug: Flumazenil 2
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil 2 mg
Trial: 2180267
Drug: Control agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control agents (cholestyramine, fibrates, probucol)
Trial: 424477
Drug: active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active medication (alpha‐flupenthixol)
Trial: 28953616
Drug: Methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40 mg) administered 30 minutes before induction of anesthesia
Trial: 28953616
Drug: Methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40 mg) administered immediately after induction of anesthesia
Trial: 23368980
Drug: Opioids (morphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids (morphine, oxycodone)
Trial: 21425574
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic treatment + fluid resuscitation)
Trial: 19588638
Drug: Fixed-combination gel
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination gel containing BPO 5% and clindamycin 1% (BPO/C) plus tretinoin microsphere gel 0.04% (RAM)
Trial: 19588638
Drug: Fixed-combination gel
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination gel containing clindamycin phosphate 1.2% and tretinoin 0.025% (CPT) plus a once-daily BPO 5% wash
Trial: 7813389
Drug: L-acetylcarnitine (LAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-acetylcarnitine (LAC) 1500 mg/day for 90 days
Trial: 7813389
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 30 days (phase T0) and further 30 days of placebo treatment (phase T3)
Trial: 2887614
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine at night
Trial: 25752401
Drug: PET-based isotoxic
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET-based isotoxic accelerated radiation therapy (PET-ART)
Trial: 25752401
Drug: Conventional fixed-dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fixed-dose CT-based radiation therapy (CRT)
Trial: 21406465
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg) administered 1 hour before stress
Trial: 18201356
Drug: PUVA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA treatment twice/week
Trial: 18201356
Drug: PUVA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA treatment three times/week
Trial: 15356084
Drug: DHEA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (100 mg/d, 3 months)
Trial: 11458055
Drug: 3-month neoadjuvant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month neoadjuvant hormonal therapy (7.5 mg leuprolide intramuscularly monthly and 250 mg flutamide orally 3 times daily)
Trial: 11458055
Drug: 8-month neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-month neoadjuvant hormonal therapy (7.5 mg leuprolide intramuscularly monthly and 250 mg flutamide orally 3 times daily)
Trial: 11458055
Drug: 3-month neoadjuvant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month neoadjuvant hormonal therapy
Trial: 11458055
Drug: 8-month neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-month neoadjuvant hormonal therapy
Trial: 9558128
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg VPA daily
Trial: 9558128
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg VPA daily
Trial: 2977273
Drug: Zoladex 3.6
RxNorm normalized name: Zoladex 3.6mg Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex 3.6 mg depot
Trial: 2977273
Drug: Diethylstilbestrol (DES)
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES) 3 mg/day
Trial: 28873028
Drug: Single intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraoperative dose of IV acetaminophen
Trial: 28873028
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative pain regimen (oral acetaminophen and ibuprofen)
Trial: 27074894
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 40 mL of 0.375% levobupivacaine and morphine patient‐controlled analgesia
Trial: 27074894
Drug: Morphine patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine patient‐controlled analgesia (Control)
Trial: 25879867
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of MVA
Trial: 11367650
Drug: Huancongdan (HCD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huancongdan (HCD) capsule
Trial: 8156307
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg/day for 2 weeks, then 11 weeks off etidronate; four cycles total) + Prednisone
Trial: 3045423
Drug: Adjuvant CYVADIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant CYVADIC chemotherapy (cyclophosphamide, vincristine, Adriamycin, and dacarbazine)
Trial: 3045423
Drug: Adjuvant VAC
RxNorm normalized name: VAC-52150
DrugBank: VAC-52150 (DB17781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant VAC chemotherapy (vincristine, actinomycin-D, and cyclophosphamide)
Trial: 31820593
Drug: Oxycodone 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.1 mg/kg
Trial: 23549409
Drug: Encapsulated oral
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated oral supplement of Bifidobacterium infantis 35624
Trial: 17126655
Drug: Hypothermic patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic patients (oral body temperature <35.8 degrees C)
Trial: 17126655
Drug: Nonhypothermic patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonhypothermic patients (oral body temperature ≥35.8 degrees C)
Trial: 11314621
Drug: Intravenous patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient‐controlled analgesia (nalbuphine HCl and ketorolac tromethamine)
Trial: 11314621
Drug: Conventional pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional pethidine HCl intramuscular group
Trial: 9146938
Drug: Topical azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical azelastine (0.254 mg per nasal cavity)
Trial: 9146938
Drug: Oral cetirizine
RxNorm normalized name: cetirizine Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cetirizine (10 mg)
Trial: 24147933
Drug: ATX‐101 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX‐101 (1 mg cm(‐2))
Trial: 24147933
Drug: ATX‐101 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX‐101 (2 mg cm(‐2))
Trial: 22571072
Drug: Structured information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured information (short video about practical aspects of the hospital stay, surgical and adjuvant treatment)
Trial: 20154074
Drug: 100% nitrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% nitrogen through a 40% venturi mask at a flow rate of 10 L/min for 2 h
Trial: 14661284
Drug: Uninformed patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninformed patients waiting for i.v. contrast material injection
Trial: 8841209
Drug: Propranolol 2
RxNorm normalized name: propranolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 2 mg IV
Trial: 1365676
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (100 mg/serving) under forced-choice condition
Trial: 6384434
Drug: Metronidazole (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (6 g/m2 given 4 hr before each of the first 3 doses of RT)
Trial: 6384434
Drug: Metronidazole (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (6 g/m2)
Trial: 25956661
Drug: Tavaborole topical
RxNorm normalized name: tavaborole topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tavaborole topical solution, 5%
Trial: 17187609
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of psychological treatment and physiotherapy (Group A)
Trial: 17187609
Drug: Integrated combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated combination of psychological treatment and somatic treatment (Group C)
Trial: 15727400
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 mcg/kg) plus midazolam (0.02 mg/kg)
Trial: 15727400
Drug: Meperidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (0.5 mg/kg) plus midazolam (0.02 mg/kg)
Trial: 31197361
Drug: bmMSC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bmMSC therapy
Trial: 28087178
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (bilateral Five Shu in Spleen Meridian), once daily for 10 consecutive days.
Trial: 28087178
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (same acupoints using Park Sham Device), once daily for 10 consecutive days.
Trial: 17096621
Drug: Various interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various interventions including counseling, education, self‐medication programs, cues and organizers, and decreasing dosing frequency.
Trial: 17096621
Drug: Decreasing dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreasing dosing frequency and self‐medication programs.
Trial: 14755979
Drug: Physical exercises
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercises 3‐5 times/week, 45‐60 min. per session, combined with antihypertensive drug therapy (Group B)
Trial: 14755979
Drug: Antihypertensive drug
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drug therapy only (Group C)
Trial: 14755979
Drug: Physical exercises
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercises and antihypertensive therapy (Group B)
Trial: 10727313
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg cyclosporine microemulsion daily
Trial: 10727313
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg cyclosporine microemulsion daily
Trial: 1552913
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (0.4 g per kilogram per day)
Trial: 1552913
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange (200 to 250 ml per kilogram of body weight)
Trial: 31053142
Drug: 3 standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 standard doses of HBV vaccination (20 μg at month 0, 1, 6)
Trial: 31053142
Drug: 4 standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 standard doses of HBV vaccination (20 μg at month 0, 1, 2, 6)
Trial: 31053142
Drug: 3 standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 standard doses of HBV vaccination
Trial: 31053142
Drug: 4 standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 standard doses of HBV vaccination
Trial: 29748420
Drug: Daily remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily remote ischaemic conditioning (rIC) for 4 weeks starting on day 3 post P‐PCI
Trial: 29748420
Drug: Daily remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily remote ischaemic conditioning (rIC)
Trial: 28256813
Drug: BUP-MOR group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP-MOR group (3 mg bupivacaine + 50 mcg morphine)
Trial: 28256813
Drug: BUP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP group (5 mg bupivacaine)
Trial: 17387332
Drug: Active nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active nicotine replacement therapy transdermal patch
Trial: 17268395
Drug: Newer M3
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer M3 receptor selective anticholinergics (solifenacin, darifenacin)
Trial: 12830340
Drug: Benazepril and
RxNorm normalized name: benazepril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril and Amlodipine combination o.d.
Trial: 11273913
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural anesthesia (TEA) combined with general anesthesia (GA) using bupivacaine 0.5% and low-dose isoflurane (0.3-0.5 vol%)
Trial: 24993695
Drug: green-plant membranes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: green-plant membranes (5 g)
Trial: 17252888
Drug: Twice‐daily atomoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice‐daily atomoxetine
Trial: 17252888
Drug: Thrice‐daily methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice‐daily methylphenidate
Trial: 14501737
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg daily (40 mg twice daily for 12 weeks)
Trial: 9217897
Drug: Acute insulin-glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute insulin-glucose infusion followed by multidose subcutaneous insulin
Trial: 9217897
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intensive insulin treatment)
Trial: 29477588
Drug: Sequential bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential bilateral rTMS (n = 20)
Trial: 27496229
Drug: Semi-individualised Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-individualised Chinese medicine treatment for 48 weeks
Trial: 23836493
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Aerobic and Resistance Training (AT+RT)
Trial: 20565376
Drug: Genzyme (Thymoglobulin:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genzyme (Thymoglobulin: ATG‐G; 6.2 +/‐ 2.9 mg/kg for 7 days)
Trial: 20565376
Drug: Fresenius (Lymphoglobulin:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresenius (Lymphoglobulin: ATG‐F; 22.6 +/‐ 7.9 mg/kg for 6 days)
Trial: 18988154
Drug: Azithromycin 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1.5% eye-drops, twice daily for 3 days
Trial: 18988154
Drug: Tobramycin 0.3%
RxNorm normalized name: TOBRAMYCIN 0.3% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 0.3% eye-drops, every 2 hours while awake for 2 days, then four times daily for 5 days
Trial: 20159729
Drug: Danqi Huogan
RxNorm normalized name: Menthol 30 mg TOPICAL PATCH [Alhua Huogan Pain Relieving Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danqi Huogan Capsule in addition to routine therapies
Trial: 20159729
Drug: Routine therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapies for liver protection
Trial: 8005276
Drug: Depot form
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot form of triptoreline (3.75 mg IM injection)
Trial: 8005276
Drug: Standard release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard release form of triptoreline (0.1 mg SC daily)
Trial: 11726845
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG solution
Trial: 27084279
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) + photodynamic therapy + oral hygiene (OH)
Trial: 27084279
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) + oral hygiene (OH)
Trial: 22797283
Drug: Magnesium lozenges,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium lozenges, administered 30 min preoperatively.
Trial: 22797283
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group), administered 30 min preoperatively.
Trial: 12204499
Drug: Ramipril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (10 mg/day)
Trial: 16003289
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (SJW) 300 mg LI 160 3 times daily
Trial: 12462291
Drug: Interferon alpha-n2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-n2b (5 MU subcutaneously once daily for 8 weeks, then 5 MU TIW for 48 weeks if HCV-RNA negative)
Trial: 12462291
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (males without a history of drug addiction)
Trial: 7473012
Drug: Fiber therapy
RxNorm normalized name: Fiber Therapy
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber therapy alone for 10 days (F)
Trial: 7473014
Drug: Fiber therapy
RxNorm normalized name: Fiber Therapy
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber therapy alone for 20 days (FF)
Trial: 1782132
Drug: Aggressive dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aggressive dietary management and treatment with pancreatic enzymes
Trial: 7025721
Drug: Oral trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimethoprim-sulfamethoxazole treatment
Trial: 26061572
Drug: Benzocaine 20%
RxNorm normalized name: BENZOCAINE 20% GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine 20% topical anesthetic
Trial: 19697825
Drug: Patient-controlled continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled continuous epidural analgesia (PCEA) with 0.125% bupivacaine and 0.2 microg kg(‐1) fentanyl (basic infusion 1 mL h(‐1), bolus 4 mL, lock‐out time 15 min)
Trial: 19697825
Drug: Remifentanil PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil PCA (0.2 microg kg(‐1) bolus doses, without basic infusion, lock‐out time 2 min)
Trial: 17896891
Drug: Rifaximin 200
RxNorm normalized name: rifAXIMin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 200 mg every 8 hours for 7 days
Trial: 17896891
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous midazolam 2 mg
Trial: 17896891
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral midazolam 6 mg
Trial: 11927450
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg morphine
Trial: 9652875
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg/d for 1 year
Trial: 7661159
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. with 1 g amoxicillin b.i.d.
Trial: 7661159
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ranitidine (900 and 1800 mg) plus sodium bicarbonate tablets 650 t.i.d. with 1 g amoxicillin b.i.d.
Trial: 1693732
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 20 mg